ArticleFunctional & integrative genomics2026
DLEU2 promotes the migration and invasion of papillary thyroid carcinoma cells through the ELAVL1/RCC2 axis.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Among the various histological types of thyroid cancer (TC), papillary thyroid carcinoma (PTC) is highly prevalent. Studies conducted in the past have revealed that the LncRNA DLEU2 is aberrantly expressed in PTC and is relevant to tumorigenesis and lymphatic metastasis. There is still uncertainty about the function and underlying mechanisms of LncRNA DLEU2 in PTC cells. Our findings indicate that DLEU2 facilitates the migration and invasion of PTC cells. Analysis from the Starbase database demonstrated a positive interaction and relationship between the RNA-binding protein (RBP) ELAVL1 and DLEU2. Fluorescence co-localization and RIP assays confirmed the binding of DLEU2 and ELAVL1 within PTC cells. ELAVL1 was found to enhance the migration and invasion of PTC cells, as demonstrated by wound healing and Transwell invasion assays. ELAVL1 preferentially binds to and stabilizes m6A-modified mRNAs. Bioinformatic analysis, western blotting, and RT-qPCR results revealed that RCC2, a downstream target of ELAVL1, was regulated by ELAVL1. MeRIP and RNA stability assays showed that ELAVL1 modulates RCC2 mRNA stability through m6A modification. Through rescue experiments, the DLEU2-ELAVL1-RCC2 axis was identified in PTC cells, demonstrating its function in cell migration and invasion. Through the Wnt5a/β-catenin signaling pathway, this axis may support epithelial-mesenchymal transition (EMT) and enhance cellular migration and invasion. Collectively, our findings elucidate the functional mechanism of the DLEU2-ELAVL1-RCC2 axis in PTC cells and provide a possible molecular target for treating PTC.
Indexed as
Identifiers
42301557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.